Retatrutide and blood pressure — multi-receptor cardiovascular effects

One concrete data point for the thread. For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.

Worth separating that from retatrutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

A narrower follow-up, since the general answer is now clear:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

BethLabQueen said:

For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds…

Senior perspective on cardiovascular risk: I'm 63 years old and started this journey skeptically. My endocrinologist recommended it after years of failed interventions.

15 months later: down 36 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Reporting back.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.

VanRx_Mike said:

Senior perspective on cardiovascular risk: I'm 63 years old and started this journey skeptically.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

• NT-proBNP: 52 pg/mL (normal, cardiac function preserved)
• Lp(a): 52 nmol/L (genetic, unchanged — expected)
• ApoB: dropped from 147 to 92 mg/dL (excellent response)
• Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.